LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Warren Gouk Sells 51,672 Shares of Stock

LifeStance Health Group, Inc. (NASDAQ:LFSTGet Rating) insider Warren Gouk sold 51,672 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $9.01, for a total transaction of $465,564.72. Following the completion of the sale, the insider now owns 6,058,627 shares of the company’s stock, valued at approximately $54,588,229.27. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Warren Gouk also recently made the following trade(s):

  • On Tuesday, September 6th, Warren Gouk sold 34,449 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $241,143.00.
  • On Tuesday, August 23rd, Warren Gouk sold 17,226 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.02, for a total transaction of $120,926.52.
  • On Monday, August 8th, Warren Gouk sold 17,226 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.30, for a total transaction of $125,749.80.
  • On Wednesday, August 3rd, Warren Gouk sold 68,904 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $482,328.00.

LifeStance Health Group Stock Performance

Shares of LFST opened at $9.23 on Friday. The company has a 50-day simple moving average of $6.69 and a 200-day simple moving average of $7.63. The company has a quick ratio of 2.19, a current ratio of 2.19 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $3.47 billion, a PE ratio of -8.88 and a beta of 1.05. LifeStance Health Group, Inc. has a 52-week low of $4.77 and a 52-week high of $16.50.

LifeStance Health Group (NASDAQ:LFSTGet Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.07). LifeStance Health Group had a negative net margin of 46.31% and a negative return on equity of 23.33%. The business had revenue of $209.53 million for the quarter, compared to analysts’ expectations of $212.47 million. During the same quarter last year, the business posted ($0.17) earnings per share. The business’s revenue was up 30.5% compared to the same quarter last year. Equities research analysts predict that LifeStance Health Group, Inc. will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LifeStance Health Group

Several hedge funds have recently added to or reduced their stakes in LFST. Harel Insurance Investments & Financial Services Ltd. purchased a new position in LifeStance Health Group during the 2nd quarter valued at about $37,000. Ameritas Investment Partners Inc. increased its holdings in LifeStance Health Group by 56.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company’s stock valued at $56,000 after acquiring an additional 2,016 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in LifeStance Health Group during the 2nd quarter valued at about $63,000. Amalgamated Bank purchased a new position in LifeStance Health Group during the 1st quarter valued at about $84,000. Finally, Virtu Financial LLC purchased a new position in LifeStance Health Group during the 2nd quarter valued at about $99,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LFST shares. Cowen cut their price target on shares of LifeStance Health Group from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Monday, August 22nd. Cowen cut their price target on shares of LifeStance Health Group from $11.00 to $10.00 in a report on Monday, August 22nd. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.33.

About LifeStance Health Group

(Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Featured Stories

Insider Buying and Selling by Quarter for LifeStance Health Group (NASDAQ:LFST)

Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.